Abstract
The $10 million Cancer Genome project, announced last week, marks China's first large-scale research program targeting a specific clinical disease. The program focuses on variations at the structural genomic and sequence levels, epigenomics, and transcriptomics, says Yang Huanming, director of the Beijing Genomics Institute. The program will carry out research into cancers that are prevalent in China, which could include lung, liver, stomach, and esophageal cancers. U.S. National Cancer Institute official Daniela Gerhard calls the project “a good idea,” noting China's unique tumor samples. Although China is a partner in the international Human Genome and HapMap projects, Gerhard says the United States will wait for more details before considering partnering on the latest effort.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
